Clinical trial
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not…
NCT00003626 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003626 |
|---|---|
| Title | Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy |
| Official title | Phase II Evaluation of Dolastatin-10 in Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | dolastatin 10 |
| Start date | Oct 1, 1998 |
| Primary completion | Dec 1, 1999 |
| Completion | May 1, 2000 |
| First posted | Aug 17, 2004 |
| Last update posted | Apr 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: